Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ECE1 | P42892 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376470 | 0.97 | MME (0.36) | MMESLC15A2BACE1 | |
| SCHEMBL29447737 | 0.96 | MME (0.36) | MMETGFBR1BACE1ECE1 | |
| SCHEMBL31474495 | 0.94 | BACE1 (0.33) | MMESLC15A2BACE1ECE1 | |
| SCHEMBL30638816 | 0.94 | MME (0.35) | MMEBACE1CA2ECE1CA1 | |
| SCHEMBL29912491 | 0.92 | MME (0.40) | MMESLC15A2 | |
| SCHEMBL29494071 | 0.92 | MME (0.40) | MMESLC15A2 | |
| SCHEMBL29383357 | 0.92 | ECE1 (0.34) | MMEECE1 | |
| SCHEMBL30209180 | 0.91 | PDCD1LG2 (0.36) | MMEBACE1CA2ECE1CA1 | |
| SCHEMBL38661411 | 0.91 | MME (0.39) | MMETGFBR1SLC15A2BACE1CA2 | |
| SCHEMBL29777856 | 0.91 | MME (0.39) | MMETGFBR1SLC15A2BACE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4241785-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4241785-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116162175-A | Influenza virus vaccine and application thereof | 西奈山伊坎医学院 | 2023-05-26 | — | — | CN | disclosed |
| EP-2758075-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | CD44, SIGLEC7, SIGLEC9 | MME 835/4885TGFBR1 4015/4885SLC15A2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.